Compare · Health Care
Elevance Health vs. Humana: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Elevance Health's revenue of $199.1B was about 1.5 times Humana's $129.7B (Cityfort calculation: one divided by the other).
Elevance Health's largest segment is Health Benefits, 69.8% of revenue in FY2025; Humana's largest segment is Insurance, 84.7% of revenue in FY2025.
Elevance Health's largest payer group is State Medicaid programs, 28.4% of revenue (FY2025); Humana's largest payer group is CMS and members, individual Medicare Advantage, 70.3% of revenue (FY2025).
Humana's page lists Elevance Health among its competitors; Elevance Health's page does not list Humana.
Each company in 5 points
Elevance Health
1 · What it sells
Elevance Health sells health plans, including Anthem Blue Cross and Blue Shield, covering 45.2 million people, and drug-benefit and care services through Carelon, with total revenues of $199.1 billion in FY2025.
Sources and detail on the Elevance Health page2 · Who pays it
In FY2025, state Medicaid programs brought in 28.4% of total revenues, employers and individuals 25.3%, Medicare 22.5%, Carelon's outside customers and other 15.3%, the Federal Employee Program 7.7% and investment income 0.8%.
Sources and detail on the Elevance Health page3 · What it keeps from $100
Of every $100 that came in during FY2025, Elevance Health spent $74.44 on members' medical care and kept $2.84 as net income after $653 million of net losses on financial instruments, while its operating gain before investment results, interest and tax was $7.2 billion.
Sources and detail on the Elevance Health page4 · Where the operating profit comes from
FY2025 operating gain was $4.2 billion in Health Benefits, $2.4 billion at CarelonRx and $960 million at Carelon Services, while Corporate & Other lost $337 million.
Sources and detail on the Elevance Health page5 · The one thing to watch
The benefit expense ratio, the share of premiums paid out for members' care, was 90.6% in Q3 FY2026, against 91.3% a year earlier.
Sources and detail on the Elevance Health page
Humana
1 · What it sells
Humana sells Medicare Advantage, Medicare drug, Medicaid and military health plans, with 18.0 million medical members at Sep 30, 2026, and runs CenterWell clinics, pharmacy and home health.
Sources and detail on the Humana page2 · Who pays it
In FY2025, individual Medicare Advantage brought in 70.3% of Humana's premiums and services revenue, Medicaid and other state contracts 11.2%, group Medicare Advantage 7.0%, Medicare drug plans 5.3%, CenterWell's outside customers 3.7% and other lines 2.4% (Cityfort calculation from the 10-K).
Sources and detail on the Humana page3 · What it keeps from $100
Of every $100 that came in during FY2025, Humana spent $85.46 on members' benefits and kept $0.92 as net income after one-off charges, while income from operations was $2.09 per $100.
Sources and detail on the Humana page4 · Where the operating profit comes from
In FY2025, the Insurance segment earned $1,664 million from operations and CenterWell $1,339 million, before $299 million of corporate costs and eliminations.
Sources and detail on the Humana page5 · The one thing to watch
The benefit ratio was 93.9% in Q3 FY2026, against 91.1% a year earlier, with $67 million of favorable prior-period reserve development, against $275 million.
Sources and detail on the Humana page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
Elevance Health
Where $100 went · FY2025
| Members' medical care (benefit expense) | $74.4 |
|---|---|
| Cost of drugs and products sold | $10.6 |
| Operating costs | $10.5 |
| Interest and amortization of acquired intangibles | $1.0 |
| Income tax | $0.5 |
| Kept as net income | $2.8 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K: each line ÷ total revenues of $199,125 million × 100. Total revenues include net investment income of $2,194 million less $653 million of net losses on financial instruments. Lines add to $100.01 because of rounding; a $1 million loss belonging to noncontrolling holders is left out. Operating gain, the company's segment measure before investment income and losses, interest, amortization of acquired intangibles and tax, was $7.2 billion, or $3.64 per $100 of operating revenue (Cityfort calculation from the FY2025 10-K).
Humana
Where $100 went · FY2025
| Members' benefits (medical and drug claims) | $85.5 |
|---|---|
| Operating costs (staff, sales and administration) | $11.9 |
| Depreciation and amortization | $0.5 |
| Interest on debt | $0.5 |
| Other costs, a business sale loss and partly owned businesses | $0.5 |
| Income tax | $0.2 |
| Kept as net income | $0.9 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K: each line ÷ total revenues of $129,664 million × 100 (premiums, services revenue and investment income). Net income of $0.92 per $100 is after $449 million of value-creation charges, $253 million of impairment charges and a $67 million loss on selling a business; income from operations was $2,704 million, or $2.09 per $100.
Line items differ because each company groups its costs its own way in its filings. Only on Elevance Health's receipt: Members' medical care (benefit expense); Cost of drugs and products sold; Operating costs; Interest and amortization of acquired intangibles. Only on Humana's receipt: Members' benefits (medical and drug claims); Operating costs (staff, sales and administration); Depreciation and amortization; Interest on debt; Other costs, a business sale loss and partly owned businesses.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
Elevance Health
Humana
See the numbers
Net income
Elevance Health
Humana
See the numbers
Free cash flow
Elevance Health
Not on the Elevance Health page.
Humana
Not on the Humana page.
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
Elevance Health
- Revenue, per year
- +9.5%
- Net income, per year
- −2.1%
Humana
- Revenue, per year
- +11.8%
- Net income, per year
- −20.2%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Elevance Health
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $51.4B | $50.7B | +1.4% |
| Net income | $1.4B | $1.2B | +14.8% |
Humana
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $41.2B | $32.6B | +26.1% |
| Net income | $162M | $195M | −16.9% |
Sources: Elevance Health S10, S9, S8, S7, S6 · Humana S7, S13, S11, S9, S5
Who pays each company
Elevance Health
- State Medicaid programs · 28.4% of revenuePremiums for Medicaid plans that states run with federal matching money: $56.6 billion, 28.4% of FY2025 total revenues (Cityfort calculation from the FY2025 10-K). Elevance does not give a figure for any single state.
- Employers and individuals · 25.3% of revenueCommercial premiums and fees, including individual plans: $50.4 billion, 25.3% of total revenues.
- Medicare members and the federal government · 22.5% of revenueMedicare Advantage, Medicare Supplement and drug plan premiums: $44.8 billion, 22.5% of total revenues.
- Carelon's outside customers and other · 15.3% of revenueDrug-benefit and care services sold outside Elevance's health plans, and other revenue: $30.5 billion, 15.3% of total revenues (Cityfort calculation from the FY2025 10-K: total operating revenue minus Health Benefits revenue).
- Federal Employee Program · 7.7% of revenuePremiums for health plans for federal government employees and their families: $15.3 billion, 7.7% of total revenues.
- Investment income · 0.8% of revenueNot a customer: net investment income of $2.2 billion less $653 million of net losses on financial instruments, $1.5 billion or 0.8% of total revenues.
Humana
- CMS and members, individual Medicare Advantage · 70.3% of revenuePremiums for individual Medicare Advantage plans: $90,403 million, 70.3% of FY2025 premiums and services revenue, as stated in the FY2025 10-K.
- States, Medicaid and other state contracts · 11.2% of revenuePremiums from state-based contracts: $14,477 million, 11.2%.
- Employers and CMS, group Medicare Advantage · 7.0% of revenuePremiums for retiree plans sold through employers: $9,014 million, 7.0%.
- CMS and members, Medicare drug plans · 5.3% of revenuePremiums for stand-alone prescription drug plans: $6,844 million, 5.3%.
- CenterWell's outside customers · 3.7% of revenuePharmacy, primary care and home health services sold outside Humana's own plans: $4,816 million, 3.7%.
- Members, Medicare Supplement and specialty plans · 1.6% of revenueMedicare Supplement ($1,098 million, 0.9%) and dental, vision and other specialty premiums ($989 million, 0.8%): 1.6% together (Cityfort calculation from the FY2025 10-K).
- Department of Defense and others, military services · 0.8% of revenueServices revenue from the TRICARE contract and other services: $1,017 million, 0.8%.
Revenue by segment
Elevance Health
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Health Benefits | $167.1B | 69.8% |
| CarelonRx | $43.4B | 18.1% |
| Carelon Services | $28.3B | 11.8% |
| Corporate & Other | $463M | 0.2% |
Humana
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Insurance | $124.6B | 84.7% |
| CenterWell | $22.5B | 15.3% |
Debt and cash
Elevance Health
Not on the Elevance Health page.
Humana
Not on the Humana page.
Who owns each company
Elevance Health
- One class of shares.
- Officers and directors as a group: 0.4% of shares (as of Mar 13, 2026).
- Vanguard Capital Management: 7.1% (as of Mar 31, 2026).
- BlackRock, Inc.: 7.8% (as of Apr 17, 2025).
Humana
- One class of shares.
- Officers and directors as a group: 0.2% of shares (as of Jan 15, 2026).
- Dodge & Cox: 9.5% (as of Mar 31, 2026).
- BlackRock, Inc.: 7.7% (as of Mar 31, 2025).
- Vanguard Capital Management: 7.6% (as of Mar 31, 2026).
Sources: Elevance Health S15, S1, S24, S23 · Humana S16, S20, S19, S18
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Elevance Health
- Blue Cross Blue Shield license
Elevance holds the Blue license in 14 states. The 10-K says it gives members access to other Blue plans' networks, which helps when selling to large employers in many states.
- Scale in health plans
Elevance had 45.2 million medical members at Dec 31, 2025 and $164.6 billion of premiums in FY2025.
- Owning drug benefits and care services
CarelonRx and Carelon Services sold $71.7 billion in FY2025 before sales between segments were removed, and earned $3.4 billion of operating gain. Core pharmacy services are done by a CVS Health subsidiary under contract.
Humana
- Medicare Advantage scale
Humana had 6.46 million individual Medicare Advantage members at Sep 30, 2026, and these plans brought in 70.3% of FY2025 premiums and services revenue.
- Its own care businesses
CenterWell ran 399 senior primary care centers with about 638,000 patients at Sep 30, 2026, plus a pharmacy and home health in 37 states.
- Government contract experience
Humana held Medicaid contracts in 10 states and the TRICARE East Region military contract in its FY2025 10-K.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Elevance Health
- Medical costs against premiums · Mixed: partly on trackBenefit expense ratio 90.6%, Q3 FY2026
- Carelon Services · Working: on track against what the company saidOperating revenue $28.3 billion, FY2025
- CarelonRx · Working: on track against what the company saidOperating gain $2.4 billion, FY2025
- Medicare Advantage · Mixed: partly on track1.9 million members, Sep 30, 2026
- Medicaid · Mixed: partly on track8.2 million members, Sep 30, 2026
Humana
- Individual Medicare Advantage members · Working: on track against what the company said+23.0% in 2026 to Sep 30
- Medicare drug plans · Working: on track against what the company saidAbout +1,220,000 individual members in 2026 to Sep 30
- CenterWell Senior Primary Care · Mixed: partly on track+146,800 patients, +49 centers in 2026 to Sep 30
- Medicaid in more states · New: recently announced13 states, with Georgia and Texas from 2027
- Star Ratings for bonus year 2028 · Early: too early to judgeCompany says its "Top Quartile" goal was exceeded
Sources: Elevance Health S6, S20, S1, S3, S5 · Humana S7, S1, S12, S14, S15, S22
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
Elevance Health
- Dividends per shareFY2021: $4.52 · FY2022: $5.12 · FY2023: $5.92 · FY2024: $6.52 · FY2025: $6.84
- Buybacks
- Dec 31, 2022: FY2022: paid $2.3 billion for its own shares. ($2.3B)
- Dec 31, 2023: FY2023: paid $2.7 billion for its own shares. ($2.7B)
- Dec 31, 2024: FY2024: paid $2.9 billion for its own shares. ($2.9B)
- Dec 31, 2025: FY2025: paid $2.6 billion for 7.4 million of its own shares. ($2.6B)
- AuditorErnst & Young LLP, since 1944
- Credit ratingS&P Global Ratings, Fitch Ratings, Moody's and AM Best (as stated in Elevance's Q3 FY2026 10-Q): A- / BBB+ / Baa2 / bbb+, outlook not stated in the filing (Sep 30, 2026)
Humana
- Dividends per shareFY2021: $2.73 · FY2022: $3.06 · FY2023: $3.44 · FY2024: $3.54 · FY2025: $3.54
- Buybacks
- Dec 31, 2022: FY2022: paid $2.1 billion for its own shares. ($2.1B)
- Dec 31, 2023: FY2023: paid $1.6 billion for its own shares. ($1.6B)
- Dec 31, 2024: FY2024: paid $817 million for its own shares. ($817M)
- Dec 31, 2025: FY2025: paid $151 million for its own shares. ($151M)
- AuditorPricewaterhouseCoopers LLP, since 1968
- Credit ratingS&P Global Ratings and Moody's (as stated in Humana's Q3 FY2026 10-Q): BBB (S&P) / Baa2 (Moody's), outlook Not stated in the filing (Sep 30, 2026)
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: pricing, regulation, legal cases, debt, customer or supplier concentration. Every risk is on each company's page.
Elevance Health
- Fewer Medicaid and Medicare Advantage members (demand)Medicaid members fell from 11.6 million at the end of FY2022 to 8.2 million at Sep 30, 2026. Medicare Advantage members fell 15.5% in the year to Sep 30, 2026, to 1.9 million.
- Investment losses (other)Net losses on financial instruments were $653 million in FY2025, including $435 million of impairments on other investments. The company estimates that a 1-point rise in interest rates would lower the market value of its bonds by about $1.6 billion.
Humana
Every risk type on the Humana page also appears on the other page.
Key facts
- How does Elevance Health make money compared with Humana?
- Elevance Health's revenue by segment in FY2025: Health Benefits 69.8%, CarelonRx 18.1%, Carelon Services 11.8%, Corporate & Other 0.2%. Humana's revenue by segment in FY2025: Insurance 84.7%, CenterWell 15.3%.
- Which is bigger by revenue, Elevance Health or Humana?
- Elevance Health reported $199.1B of revenue in FY2025, and Humana reported $129.7B in FY2025.
- How much net income did Elevance Health and Humana report?
- Elevance Health reported net income of $5.7B in FY2025, and Humana reported $1.2B in FY2025.
- How much of every $100 did Elevance Health and Humana keep as net income?
- Elevance Health kept $2.8 of every $100 that came in during FY2025, and Humana kept $0.9 in FY2025 (Cityfort calculation from each company's annual report).
- When do Elevance Health's and Humana's fiscal years end?
- Elevance Health: December 31. Humana: December 31.
Built from each company's page. Elevance Health updated Nov 6, 2026; Humana updated Nov 7, 2026.
Sources
Elevance Health
- S1Form 10-K, fiscal year 2025 (ended Dec 31, 2025), Elevance Health, Inc. (SEC EDGAR), Feb 6, 2026
- S3Form 10-K, fiscal year 2023 (ended Dec 31, 2023), Elevance Health, Inc. (SEC EDGAR), Feb 21, 2024
- S5Form 10-Q, Q3 FY2026 (quarter ended Sep 30, 2026), Elevance Health, Inc. (SEC EDGAR), Oct 21, 2026
- S6Q3 FY2026 earnings release (8-K Ex. 99.1, Oct 21, 2026), Elevance Health, Inc. (SEC EDGAR), Oct 21, 2026
- S7Q2 FY2026 earnings release (8-K Ex. 99.1, Jul 15, 2026), Elevance Health, Inc. (SEC EDGAR), Jul 15, 2026
- S8Q1 FY2026 earnings release (8-K Ex. 99.1, Apr 22, 2026), Elevance Health, Inc. (SEC EDGAR), Apr 22, 2026
- S9Q4 FY2025 earnings release (8-K Ex. 99.1, Jan 28, 2026), Elevance Health, Inc. (SEC EDGAR), Jan 28, 2026
- S10Q3 FY2025 earnings release (8-K Ex. 99.1, Oct 21, 2025), Elevance Health, Inc. (SEC EDGAR), Oct 21, 2025
- S152026 proxy statement (DEF 14A, annual meeting May 13, 2026), Elevance Health, Inc. (SEC EDGAR), Mar 27, 2026
- S20Form 8-K (Item 7.01), 2026 guidance reaffirmed (Sep 10, 2026), Elevance Health, Inc. (SEC EDGAR), Sep 10, 2026
- S23Schedule 13G/A by The Vanguard Group (0 shares after internal realignment), The Vanguard Group (SEC EDGAR), Mar 26, 2026
- S24Schedule 13G by Vanguard Capital Management (7.13%, event date Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), Apr 29, 2026
Humana
- S1Form 10-K, fiscal year 2025 (ended Dec 31, 2025), Humana Inc. (SEC EDGAR), Feb 19, 2026
- S3Form 10-K, fiscal year 2023 (ended Dec 31, 2023), Humana Inc. (SEC EDGAR), Feb 15, 2024
- S4Form 10-K, fiscal year 2022 (ended Dec 31, 2022), Humana Inc. (SEC EDGAR), Feb 16, 2023
- S5Form 10-Q, Q3 FY2026 (quarter ended Sep 30, 2026), Humana Inc. (SEC EDGAR), Nov 6, 2026
- S7Q3 FY2026 detailed earnings release and statistical supplement (8-K Ex. 99.2), Humana Inc. (SEC EDGAR), Nov 6, 2026
- S9Q2 FY2026 detailed earnings release and statistical supplement (8-K Ex. 99.2), Humana Inc. (SEC EDGAR), Jul 29, 2026
- S11Q1 FY2026 detailed earnings release and statistical supplement (8-K Ex. 99.2), Humana Inc. (SEC EDGAR), Apr 29, 2026
- S12Q4 FY2025 earnings release (8-K Ex. 99.1), Humana Inc. (SEC EDGAR), Feb 11, 2026
- S13Q4 FY2025 detailed earnings release and statistical supplement (8-K Ex. 99.2), Humana Inc. (SEC EDGAR), Feb 11, 2026
- S14Q3 FY2026 prepared management remarks (Nov 6, 2026; no Q&A), Humana Inc. (SEC EDGAR), Nov 6, 2026
- S15Q4 FY2025 prepared management remarks (Feb 11, 2026; no Q&A), Humana Inc. (SEC EDGAR), Feb 11, 2026
- S162026 proxy statement (DEF 14A), Humana Inc. (SEC EDGAR), Mar 6, 2026
- S18Schedule 13G/A, The Vanguard Group (event Mar 13, 2026), The Vanguard Group (SEC EDGAR), Mar 27, 2026
- S19Schedule 13G, Vanguard Capital Management (event Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), Apr 30, 2026
- S20Schedule 13G/A, Dodge & Cox (event Mar 31, 2026), Dodge & Cox (SEC EDGAR), May 14, 2026
- S22Form 8-K, Item 7.01: 2027 Medicare Advantage Star Ratings, Humana Inc. (SEC EDGAR), Oct 9, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.